ARDELYX, INC.
ARDXCIK 0001437402 · Pharmaceutical Preparations · Nasdaq
- NTERYX INC (until 2008-06-09)
Revenue (TTM)
$376.58M
+22.1% YoY
Q1 Apr 2026
Net Income (TTM)
−$98.8M
−57.4% YoY
Q1 Apr 2026
EPS Diluted (TTM)
−$0.40
−52.9% YoY
Q1 Apr 2026
Gross Margin
0.7%
Q1 Apr 2026
Operating Margin
-20.9%
Q1 Apr 2026
Net Margin
-26.2%
Q1 Apr 2026
Free Cash Flow (TTM)
−$151.77M
Q1 Apr 2026
Cash
$31.21M
Q1 Apr 2026
Total Debt
$26.54M
Q1 Apr 2026
Shares Outstanding
247.03M sh
Q1 Apr 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Low Neutral
Ardelyx (ARDX) Stockholders OK 9M Share Plan Increase
The biotech company won investor approval to add 9 million shares to its equity compensation pool.